The FDA has approved a nasal antihistamine for nonprescription use in the treatment of seasonal and perennial allergic rhinitis in individuals aged 6 years and older.
The FDA has approved a nasal antihistamine for nonprescription use in the treatment of seasonal and perennial allergic rhinitis in individuals aged 6 years and older.
The FDA has approved a nasal antihistamine for nonprescription use in the treatment of seasonal and perennial allergic rhinitis in individuals aged 6 years and older.
The accelerated approval pathway is used when a medication is found to provide a significant advantage over other approved treatments for serious or life-threatening conditions.
The US Food and Drug Administration has approved a drug for chronic weight management in adults with overweight or obesity and at least one weight-related condition.
The approval comes after positive results from the LIBERTY 1 and 2 studies were published, which showed safety and efficacy of the medication after 24 weeks.
The approval comes after positive results from the LIBERTY 1 and 2 studies were published, which showed safety and efficacy of the medication after 24 weeks.
The approval comes after positive results from the LIBERTY 1 and 2 studies were published, which showed safety and efficacy of the medication after 24 weeks.
